© 2022 BioMarin. All rights reserved.

Back to Leadership

Philip Lo Scalzo joined BioMarin in 2007 and currently serves as our Senior Vice President, Global Compliance & Ethics and Chief Compliance Officer. In his role, Mr. Lo Scalzo is responsible for creating and maintaining our global compliance program, which includes Healthcare Compliance, GxP Compliance, Internal Audit, and Global Security. His responsibilities include overseeing the development and implementation of compliance policies, as well as employee and partner training; managing GxP audits of both company facilities and vendors; scoping and executing financial and operational internal audits, including audits of third-party vendors; coordinating enterprise risk assessments and analysis; review and approval of promotional materials; monitoring of promotional events and other interactions with healthcare professionals; management of investigations; implementation of corrective actions; and oversight of the global security program, which focuses on physical and personnel security.

Prior to this role, Mr. Lo Scalzo served as BioMarin’s Deputy General Counsel, working on a variety of legal and corporate compliance related matters. Before joining BioMarin, he spent four years at Sanofi-Aventis, where he served as an Assistant General Counsel supporting the organization’s cardiovascular commercial team, corporate compliance department, litigation and human resources groups. Prior to joining Sanofi-Aventis, Mr. Lo Scalzo was an associate attorney in the New York office of Sedgwick, Detert, Moran & Arnold, where his practice primarily focused on defending pharmaceutical product liability cases.

Mr. Lo Scalzo received a J.D. from Brooklyn Law School and a B.A. from Boston College. He currently serves as executive Leader Liaison for the BioMarin Veterans Employee Resource Group.


Our Pipeline

We maximize the impact of genetic innovation to develop transformative therapies.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

View Now Our Pipeline